Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Buletin Poltanesa
Nurmalasari, Andriana
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Computer Science & IT Education

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Identification of Inhibiting and Supporting Factors for Managerial Performance at PT Anugrah as a Pharmaceutical Company Nurmalasari, Andriana; Harsono, Deti Mulyo
Poltanesa Vol 26 No 1 (2025): June 2025
Publisher : P3KM Politeknik Pertanian Negeri Samarinda

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51967/tanesa.v26i1.3262

Abstract

This study aims to identify the inhibiting and supporting factors affecting managerial Performance at PT Anugrah, a leading pharmaceutical company in Indonesia. Using a qualitative case study approach, data were collected through in-depth interviews with 15 middle-to-senior level managers and analysis of company documents. Thematic analysis revealed that managerial Performance is primarily supported by transformational leadership, regular competency development programs, and a transparent performance-based reward system. Conversely, key inhibiting factors include excessive bureaucratic procedures interdepartmental communication gaps, and inadequate digital infrastructure. The findings align with existing literature on performance management while highlighting industry-specific challenges in the highly regulated pharmaceutical sector. The study provides practical recommendations for PT Anugrah   including leadership development initiatives, streamlining operational processes, and enhancing digital transformation efforts. These findings contribute to the broader discourse on human resource management in regulated industries, offering insights for similar pharmaceutical companies seeking to optimize managerial effectiveness. Limitations include the single-company focus and potential respondent bias, suggesting the need for future quantitative studies across multiple pharmaceutical firms to validate these findings.
Co-Authors Harsono, Deti Mulyo